Gain Therapeutics, Inc.
GANX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GANX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GANX
Gain Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases, with its lead candidate GT-02287 in Phase 1b/2 clinical trials for GBA1-related Parkinson's disease.
Key risk: Need for additional financing
BioSniper Score
Based on 5 of 6 signals
Market Cap
$77.2M
Cash Runway
8.8 moLead Asset
gt-02287 (Phase 1)
Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for Gain Therapeutics, Inc..
Similar companies
Gain Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases, with its lead candidate GT-02287 in Phase 1b/2 clinical trials for GBA1-related Parkinson's disease.
- Lead product candidate GT-02287 is being evaluated in a Phase 1b clinical study with an open-label extension, and a Phase 2 study is expected to initiate in Q3 2026 [news · 2026-07-16].
- Cash and equivalents were $13.1M as of 2026-06-30, with a net loss of -$4.7M for the six months ended June 30, 2026 [sec].
- The company expects its current cash to fund operations into Q2 2027, including completion of the Phase 1b open-label extension in October 2026 [news · 2026-07-16].
- Gain Therapeutics also has an earlier-stage pipeline candidate, GT-04686, and a platform technology called rexaceract [sec_mda · as of 2026-08-11].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2025-11-12].
What works
- GT-02287 has completed enrollment in its Phase 1b study faster than anticipated, with biomarker data expected in Q4 2025 [sec_mda · as of 2025-08-12].
- The company has a cash runway into Q2 2027, providing a buffer to reach key clinical milestones [news · 2026-07-16].
- Gain Therapeutics is advancing a novel platform (rexaceract) for structure-based drug design, which may support future pipeline expansion [sec_mda · as of 2026-08-11].
What to weigh
- The company has a history of operating losses and expects to need significant additional financing to continue operations beyond its current cash runway [sec_mda · as of 2026-05-11].
- GT-02287 is still in early clinical development; there is no guarantee of successful completion of ongoing or planned trials [sec · filed 2026-03-18].
- Global macroeconomic conditions and capital market volatility may impair the company's ability to raise funds on favorable terms [sec_mda · as of 2026-08-11].
- The company has no approved products and no revenue from commercial sales, making it entirely dependent on external funding [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Cash runway into Q2 2027
“its current cash and cash equivalents are anticipated to fund the Company's operations into the second quarter of 2027”
News · July 16, 2026
Phase 1b enrollment completed faster than anticipated
“faster-than-anticipated completion of enrollment in our ongoing Phase 1b clinical study evaluating the safety and tolerability of GT-02287”
SEC MD&A · August 12, 2025
Catalyst timeline
- 2026-09-30 · Phase2_Topline · gt-02287 — Phase 2 Readout: gt-02287 — Topline results from the Phase 2 study of GT-02287 are expected, which will provide initial efficacy and safety data in GBA1-Parkinson's disease patients.
Risks & what to watch (4)›
Key risks
- Need for additional financing — The company expects to require significant additional funding to continue operations beyond current cash runway [sec_mda · as of 2026-05-11].
- Clinical development risk
- No approved products or revenue — The company has no marketed products and no revenue from commercial sales [sec_mda · as of 2025-11-12].
- Market and economic uncertainty — Global macroeconomic conditions and capital market volatility may hinder fundraising efforts [sec_mda · as of 2026-08-11].
What to watch
- Phase 1b open-label extension results expected in October 2026 [news · 2026-07-16].
- Initiation of Phase 2 clinical study for GT-02287 in Q3 2026 [news · 2026-07-16].
- Biomarker data from Phase 1b study expected in Q4 2025 [sec_mda · as of 2025-08-12].
- Any updates on regulatory submissions or partnership agreements for GT-02287 or GT-04686 [sec · filed 2026-03-18].
Sources: News · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Gain Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gain Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
8.8 months
D/E 0.37 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~31d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
40
Total value held
$12.0M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 1,769,788 | $3.4M |
| vanguard capital management llc | 799,772 | $1.6M |
| jones financial companies lllp | 631,615 | $1.2M |
| susquehanna international group, llp | 469,567 | $911K |
| geode capital management, llc | 447,342 | $869K |
| jane street group, llc | 255,483 | $496K |
| vanguard fiduciary trust co | 229,979 | $446K |
| blackrock, inc. | 225,046 | $437K |
| ubs group ag | 220,489 | $428K |
| cresset asset management, llc | 160,000 | $310K |
Showing top 10 of 40 institutional holders of Gain Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.3%
- Days to cover
- 6.2
- Shares short
- 3,442,408
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GANX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Gain Therapeutics, Inc.?
Gain Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases, with its lead candidate GT-02287 in Phase 1b/2 clinical trials for GBA1-related Parkinson's disease.
What is Gain Therapeutics, Inc.'s lead drug candidate?
Gain Therapeutics, Inc.'s most advanced tracked candidate is gt-02287 (Phase 1) for Parkinson Disease.
What is Gain Therapeutics, Inc.'s next catalyst?
Gain Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: gt-02287" — expected September 30, 2026.
Who is the CEO of Gain Therapeutics, Inc.?
Mr. Gene Mack M.B.A. is the chief executive officer of Gain Therapeutics, Inc. (GANX).
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. (GANX) is headquartered in Bethesda, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.